Cargando…
True prevalence of long-COVID in a nationwide, population cohort study
Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 S...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689486/ https://www.ncbi.nlm.nih.gov/pubmed/38036541 http://dx.doi.org/10.1038/s41467-023-43661-w |
_version_ | 1785152378178109440 |
---|---|
author | Hastie, Claire E. Lowe, David J. McAuley, Andrew Mills, Nicholas L. Winter, Andrew J. Black, Corri Scott, Janet T. O’Donnell, Catherine A. Blane, David N. Browne, Susan Ibbotson, Tracy R. Pell, Jill P. |
author_facet | Hastie, Claire E. Lowe, David J. McAuley, Andrew Mills, Nicholas L. Winter, Andrew J. Black, Corri Scott, Janet T. O’Donnell, Catherine A. Blane, David N. Browne, Susan Ibbotson, Tracy R. Pell, Jill P. |
author_sort | Hastie, Claire E. |
collection | PubMed |
description | Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 Scottish adults. 98,666 (49.8%) had symptomatic laboratory-confirmed SARS-CoV-2 infections and 99,430 (50.2%) were age-, sex-, and socioeconomically-matched and never-infected. While 41,775 (64.5%) reported at least one symptom 6 months following SARS-CoV-2 infection, this was also true of 34,600 (50.8%) of those never-infected. The crude prevalence of one or more symptom attributable to SARS-CoV-2 infection was 13.8% (13.2%,14.3%), 12.8% (11.9%,13.6%), and 16.3% (14.4%,18.2%) at 6, 12, and 18 months respectively. Following adjustment for potential confounders, these figures were 6.6% (6.3%, 6.9%), 6.5% (6.0%, 6.9%) and 10.4% (9.1%, 11.6%) respectively. Long-COVID is characterised by a wide range of symptoms that, apart from altered taste and smell, are non-specific. Care should be taken in attributing symptoms to previous SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-10689486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106894862023-12-02 True prevalence of long-COVID in a nationwide, population cohort study Hastie, Claire E. Lowe, David J. McAuley, Andrew Mills, Nicholas L. Winter, Andrew J. Black, Corri Scott, Janet T. O’Donnell, Catherine A. Blane, David N. Browne, Susan Ibbotson, Tracy R. Pell, Jill P. Nat Commun Article Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 Scottish adults. 98,666 (49.8%) had symptomatic laboratory-confirmed SARS-CoV-2 infections and 99,430 (50.2%) were age-, sex-, and socioeconomically-matched and never-infected. While 41,775 (64.5%) reported at least one symptom 6 months following SARS-CoV-2 infection, this was also true of 34,600 (50.8%) of those never-infected. The crude prevalence of one or more symptom attributable to SARS-CoV-2 infection was 13.8% (13.2%,14.3%), 12.8% (11.9%,13.6%), and 16.3% (14.4%,18.2%) at 6, 12, and 18 months respectively. Following adjustment for potential confounders, these figures were 6.6% (6.3%, 6.9%), 6.5% (6.0%, 6.9%) and 10.4% (9.1%, 11.6%) respectively. Long-COVID is characterised by a wide range of symptoms that, apart from altered taste and smell, are non-specific. Care should be taken in attributing symptoms to previous SARS-CoV-2 infection. Nature Publishing Group UK 2023-11-30 /pmc/articles/PMC10689486/ /pubmed/38036541 http://dx.doi.org/10.1038/s41467-023-43661-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hastie, Claire E. Lowe, David J. McAuley, Andrew Mills, Nicholas L. Winter, Andrew J. Black, Corri Scott, Janet T. O’Donnell, Catherine A. Blane, David N. Browne, Susan Ibbotson, Tracy R. Pell, Jill P. True prevalence of long-COVID in a nationwide, population cohort study |
title | True prevalence of long-COVID in a nationwide, population cohort study |
title_full | True prevalence of long-COVID in a nationwide, population cohort study |
title_fullStr | True prevalence of long-COVID in a nationwide, population cohort study |
title_full_unstemmed | True prevalence of long-COVID in a nationwide, population cohort study |
title_short | True prevalence of long-COVID in a nationwide, population cohort study |
title_sort | true prevalence of long-covid in a nationwide, population cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689486/ https://www.ncbi.nlm.nih.gov/pubmed/38036541 http://dx.doi.org/10.1038/s41467-023-43661-w |
work_keys_str_mv | AT hastieclairee trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT lowedavidj trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT mcauleyandrew trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT millsnicholasl trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT winterandrewj trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT blackcorri trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT scottjanett trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT odonnellcatherinea trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT blanedavidn trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT brownesusan trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT ibbotsontracyr trueprevalenceoflongcovidinanationwidepopulationcohortstudy AT pelljillp trueprevalenceoflongcovidinanationwidepopulationcohortstudy |